New hope for frail lung cancer patients: Chemo-Free combo shows promise
NCT ID NCT04351256
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of thoracic radiotherapy and the immunotherapy drug durvalumab in 51 elderly or frail patients with stage III lung cancer who could not receive chemotherapy. The goal was to see if this approach is safe and can shrink tumors. The study focused on side effects like lung inflammation and how well the cancer responded after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (Imfinzi) plus thoracic radiotherapy
What this could lead to
If successful, this could offer a treatment option for elderly or frail patients with stage III lung cancer who cannot tolerate chemotherapy.
What could go wrong
This is a small phase II trial with only 51 participants, so results may not apply to all patients. The main risk is lung inflammation (pneumonitis) from the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC, STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DRK Kliniken Berlin-Mitte
Berlin, 13359, Germany
-
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, 48153, Germany
-
Kliniken Maria Hilf GmbH
Mönchengladbach, 41063, Germany
-
Kliniken der Stadt Köln gGmbH, Lungenklinik Merheim
Cologne, 51109, Germany
-
Klinikum Ludwigsburg
Ludwigsburg, 71640, Germany
-
Lungenklinik Hemer, Pneumologie und Thorakale Onkologie
Hemer, 58675, Germany
-
Onkodok GmbH
Gütersloh, 33332, Germany
-
Pi.Tri-Studien GmbH
Offenburg, 77654, Germany
-
Sana Klinikum Offenbach GmbH
Offenbach, 63069, Germany
-
Thoraxklinik am Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
-
Universitätsklinikum Aachen
Aachen, 52074, Germany
-
Universitätsmedizin Göttingen
Göttingen, 37075, Germany
-
Universitätsmedizin Mainz
Mainz, 55131, Germany
-
Vincentius-Diakonissen-Kliniken gAG
Karlsruhe, 76137, Germany